Navigation Links
Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
Date:4/21/2008

BATON ROUGE, La., April 21 /PRNewswire-USNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) delivered a new report today on medicines in the research pipeline. The report found America's pharmaceutical research companies are testing a record 750 new medicines to help treat cancer.

"We released this report in Baton Rouge because of its particular relevance to the health of the population in Louisiana," says PhRMA Senior Vice President Ken Johnson. The report was unveiled at the State Capitol Building. "According to the Centers for Disease Control and Prevention, Louisiana has the highest death rate from cancer in the United States. In fact, recent data from the American Cancer Society tells us that African American men in Louisiana have the highest death rate and shortest survival rate in the country for all cancers combined, which is why we are releasing this report here to coincide with National Cancer Minority Awareness Week."

The medicines in the report are being tested in human clinical trials or are awaiting approval by the U.S. Food and Drug Administration.

"The medicines now in the research pipeline will add to the substantial progress made in the last five years by biopharmaceutical companies in developing new and more effective cancer treatments," notes PhRMA President and CEO Billy Tauzin. "This strong commitment to research is a product of the determination of the men and women working for America's pharmaceutical research companies to develop new medicines that will enable patients to live longer, healthier, and more productive lives. I am one of those patients who was diagnosed with cancer and was given a new treatment that brought me from the brink of death back to life."

Cancer medicines being developed include 113 for lung cancer, the leading cause of cancer death in the United States; 90 for breast cancer, which is expected to strike more than 180,000 American women this year; 65 for colorectal cancer, which is the third most common cancer in both men and women; and 88 for prostate cancer, which this year is expected to kill 28,000 American men. Additional medicines target brain cancer, kidney cancer, ovarian cancer, pancreatic cancer, skin cancer and others.

The medicines represent many cutting-edge approaches, including one medicine that targets and kills specific cancer cells, and then activates the patient's general immune system to destroy any remaining cancer.

"Researchers are making exciting progress in the search for new cures and treatments for cancer. But these efforts are wasted if the medicines we develop aren't accessible to patients who need them," says Johnson.

Help is available to patients in need through the Partnership for Prescription Assistance, a program sponsored by America's pharmaceutical research companies. To date, the PPA has helped nearly 5 million patients nationwide, including more than 112,000 people in Louisiana. Since its launch in April 2005, the PPA bus tour has visited all 50 states and more than 2,000 cities to educate people about patient assistance programs. The PPA bus has been to Louisiana seven times since the program was launched. Just last month, the bus, along with Montel Williams, was in Baton Rouge for a special event at the Louisiana State Capitol.

The "Help is Here Express" is staffed by trained specialists able to quickly help uninsured patients in need access information on more than 475 patient assistance programs, including nearly 200 programs offered by pharmaceutical companies. When the "Help is Here Express" moves on, patients can visit PPA's easy-to-use Web site (http://www.pparx.org) or call the toll-free phone number (1-888-4PPA-NOW).

To read the Medicines in Development for Cancer 2008 on the PhRMA web site, click on the following link: http://www.phrma.org

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://www.innovation.org/

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org/

For information on the dangers of imported drugs, visit: http://www.buysafedrugs.info/

CONTACT: Pamela Squires of the Pharmaceutical Research and Manufacturers of America, +1-202-835-3460


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis
2. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
3. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
4. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
5. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
6. NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection
7. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
8. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
9. Independent Studies Report on Possible Roles for Cylexs Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
10. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 /PRNewswire/ ... diabetes. In a further effort to help spread lessons ... this condition, the International Diabetes Federation (IDF) and Eli ... come together for the second phase of the Bringing ... (BRIDGES 2), reaffirming their commitment to helping people with ...
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
(Date:6/7/2017)... URBANDALE, Iowa , June 6, 2017  Diplomat Specialty Infusion ... a sterile compounding environment to its Iowa ... Urbandale now features an ISO 7 cleanroom—the ... a controlled environment with a low level of pollutants. ... serve more IV nutrition consumers and better serve our ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... As we celebrate our ... dog, and that makes it the perfect time to celebrate National Hot Dog Month. ... eat 150 million hot dogs on July 4th alone and while they enjoy many ...
(Date:6/28/2017)... ... 28, 2017 , ... Drs. Steven Crandall, Karen Johnson and Kathy Lopez are ... Upper St. Clair, PA, without a referral. The doctors address jaw pain ... temporomandibular joint and facial muscles that support it. , Jaw pain can be ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the ... 62 minutes, at least one person dies as a direct result from an eating ... exists for qualified treatment providers. The iaedp Foundation meets this challenge by offering what ...
(Date:6/28/2017)... ... June 28, 2017 , ... Park Systems , a leader ... all SEMICONWest attendees and Park customers on July 11, 2017 from 12-2pm ... Sang-il Park, Chairman & CEO of Park Systems, and Prof. Krishna Saraswat , ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers Insurance Agency, ... in northern Virginia and DC, is announcing a cooperative charity event in conjunction ... and other disorders that lead to memory impairment. , The Insight Memory Care ...
Breaking Medicine News(10 mins):